NCT04250116CompletedPhase 4
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents (ADAPT AF-DES)
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
Atrial fibrillation patients with risk factors for stroke and systemic embolism require long-term anticoagulant therapy. Recently, non-vitamin K antagonist oral anticoagulant (NOAC) has shown their excellent safety and efficacy, and thus are widely accepted in clinical practice. Meanwhile, after percutaneous coronary intervention (PCI) using the drug-eluting stents due to coronary artery disease, the administration of one or more antiplatelets is essential to prevent the recurrence of stent thrombosis and myocardial infarction. Combined administration of anticoagulants and antiplatelets significantly lowers the incidence of ischemic events such as stroke and myocardial infarction, however, it also significantly increases the likelihood of bleeding leading to hospitalization, and or even death, thereby significantly affecting the clinical course of the AF patients who underwent PCI. Nevertheless, due to the very high mortality rate of stent thrombosis, the current standard of care guidelines recommend triple therapy with anticoagulants and double antiplatelet therapy (DAPT) in patients with atrial fibrillation for 1 month after coronary intervention, followed by co-administration of NOAC with single antiplatelet agent for 1 year. However, little is known after the optimal therapeutic strategy after 1 year. The purpose of this study is to compare the clinical results of single anticoagulant and clopidogrel combination therapy for maintenance therapy after 1 year in patients with atrial fibrillation.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 960 (actual)
- First submitted
- 19 Jan 2020
- Start date
- 28 Apr 2020
- Primary completion date
- 8 May 2026
- Lead sponsor
- Yonsei University
- Diseases
- Atrial fibrillation
- NCT number
- NCT04250116
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 960
- From 28 Apr 2020 to the primary completion date, 8 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients treated with 1st generation drug-eluting stents (Cypher, Taxus, or Endeavor Sprint)
Other illness
- Requiring anticoagulation due to history of mechanical valve replacement, mitral stenosis or deep vein thrombosis
- Intracerebral hemorrhage within 2 months
- Patients with gastrointestinal hemorrhage within three months of registration
Lab values
- Coagulopathy, continuous bleeding, or Hb level below 10 g/dL
Age
- Over 85 years old
Other
- Pregnancy or Potential Pregnancy
- Life expectancy within 1 year
- Patients who refuse or do not understand the written consent form
- Patients diagnosed with a gastrointestinal tumor that requires continuous treatment
Who the study is looking for
- over 19 years old
- Patient who underwent PCI with DES more than 12 months ago
- Non-valvular atrial fibrillation patients requiring long-term anticoagulation
Age in the registry: 19 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Severance Cardiovascular Hospital, Yonsei University Health System Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
Related publications
- Antithrombotic Therapy in Patients With Atrial Fibrillation With Prior Complex PCI: A Secondary Analysis of the Randomized ADAPT AF-DES Trial.Circ Cardiovasc Interv · 2026 · PMID 42464814
- Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.N Engl J Med · 2026 · PMID 41211917
This page is information, not medical advice. Discuss any trial with your doctor.